David Emanuelson

Senior Counsel-Legal Antitrust at Novartis AG

David Emanuelson

David Emanuelson

Senior Counsel-Legal Antitrust at Novartis AG

Biography

David Emanuelson is a Senior Associate in Baker Botts’ Antitrust and Competition Practice and a resident in the firm’s Washington, D.C. office. He has substantial experience in every major aspect of antitrust law, having represented clients in domestic and foreign government investigations, mergers and acquisitions and private civil cases, as well as regularly providing counseling advice for the avoidance of antitrust actions. Mr. Emanuelson has represented many of the world’s leading companies in the technology, telecommunications, chemicals, pharmaceuticals, consumer products and airline industries.

Mr. Emanuelson regularly advises clients on mergers and acquisitions, joint ventures, licensing arrangements, sales and distribution arrangements, and trade association activities. He has substantial experience in defending clients against government investigations brought by the Federal Trade Commission, in both the antitrust and consumer protection fields.

A particular emphasis on Mr. Emanuelson’s practice is in cases involving dominant firm conduct and the intersection of antitrust and intellectual property rights. His notable engagements include representing Intel Corporation in broad-ranging private litigation, as well as government actions brought by the Federal Trade Commission, European Commission, Korea Fair Trade Commission, and Japan Fair Trade Commission, which revolved around Intel’s discounting and IP licensing practices. Mr. Emanuelson also represented Qualcomm Inc. in response to a similar challenge by the EC and KFTC.

Mr. Emanuelson represents clients in criminal cartel investigations, as well as follow-on private litigation in response to government actions. He has substantial experience in civil litigation, representing both plaintiffs and defendants. For example, Mr. Emanuelson has argued cases in front of the Seventh Circuit Court of Appeals, state superior courts, and administrative bodies.

Mr. Emanuelson is the co-chair of the Antitrust Group’s e-discovery practice, designed to develop and refine “best practices” for complying with government and private e-discovery requirements, and he has substantial experience implementing cost-effective e-discovery strategies on behalf of clients. He is also active in several committees of the ABA Antitrust Section and regularly serves as a drafter of the annual supplements to Antitrust Law Developments.

Overview
RelSci Relationships

1288

Contact Data
Trying to get in touch with David Emanuelson? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals David Emanuelson likely has professional access to. A relationship does not necessarily indicate a personal connection.

Partner at Hogan & Lovells LLP

Relationship likelihood: Strong

Partner Norton Rose Fulbright US LLP at Norton Rose Fulbright

Relationship likelihood: Strong

Counsel at Hogan & Lovells LLP

Relationship likelihood: Strong

Practice Area Attorney at Cravath, Swaine & Moore LLP

Relationship likelihood: Strong

Kaye Scholer LLP

Relationship likelihood: Strong

Partner at Kirkland & Ellis LLP

Relationship likelihood: Strong

Partner at Hogan & Lovells LLP

Relationship likelihood: Strong

Partner at Linklaters LLP

Relationship likelihood: Strong

Managing Partner at Freshfields Bruckhaus Deringer LLP

Relationship likelihood: Strong

Partner at Freshfields Bruckhaus Deringer LLP

Relationship likelihood: Strong

In The News
The Washington Post
November 27, 2014
Home sales
Paths to David Emanuelson
Potential Connections via
Relationship Science
You
David Emanuelson
Senior Counsel-Legal Antitrust at Novartis AG
Career History
Senior Counsel-Legal Antitrust
Current

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Senior Associate
Prior

Baker Botts LLP provides legal services to regional, national and international clients. Its clients include Halliburton, Centerpoint Energy, and ExxonMobil. The firm has offices in Austin, Beijing, Dallas, Dubai, Hong Kong, Houston, London, Moscow, New York, Riyadh, and Washington. The company was founded in 1840 and is located in Houston, Texas.

Transactions
Details Hidden

GlaxoSmithKline Plc purchases Novartis AG /Human Vaccines Operations from Novartis AG

Details Hidden

Eli Lilly & Company purchases Elanco Tiergesundheit AG from Novartis AG

Other Affiliations

David Emanuelson is affiliated with Novartis AG, Baker Botts LLP

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by David Emanuelson. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of David Emanuelson's profile does not indicate a business or promotional relationship of any kind between RelSci and David Emanuelson.